Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion.
Rasonglès P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP. Rasonglès P, et al. Among authors: sundin d. Transfusion. 2009 Jun;49(6):1083-91. doi: 10.1111/j.1537-2995.2009.02111.x. Epub 2009 Feb 27. Transfusion. 2009. PMID: 19309473
An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padrón F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. Osselaer JC, et al. Among authors: sundin d. Vox Sang. 2008 May;94(4):315-23. doi: 10.1111/j.1423-0410.2007.01035.x. Epub 2008 Jan 30. Vox Sang. 2008. PMID: 18248574
An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
Cazenave JP, Waller C, Kientz D, Mendel I, Lin L, Jacquet M, Propst M, Liu W, Corash L, Sundin D, Defoin L, Messe N, Osselaer JC. Cazenave JP, et al. Among authors: sundin d. Transfusion. 2010 Jun;50(6):1210-9. doi: 10.1111/j.1537-2995.2009.02579.x. Epub 2010 Jan 22. Transfusion. 2010. PMID: 20113450 Clinical Trial.
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J. Vincent JL, et al. Crit Care Med. 2005 Oct;33(10):2266-77. doi: 10.1097/01.ccm.0000181729.46010.83. Crit Care Med. 2005. PMID: 16215381 Clinical Trial.
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Nadel S, et al. Among authors: sundin dp. Lancet. 2007 Mar 10;369(9564):836-843. doi: 10.1016/S0140-6736(07)60411-5. Lancet. 2007. PMID: 17350452 Clinical Trial.
Effects of drotrecogin alfa (activated) in human endotoxemia.
Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Kalil AC, et al. Shock. 2004 Mar;21(3):222-9. doi: 10.1097/01.shk.0000116778.27924.79. Shock. 2004. PMID: 14770034 Clinical Trial.
88 results